MedTrace Logo

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

NCT05263492 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2025-10-02

Study results available
· View outcomes & findings →

Summary

Determine the efficacy of the combination of lenvatinib and pembrolizumab in Black participants

Conditions

Interventions

DRUG

Lenvatinib

Lenvatinib once a day by mouth every day

DRUG

Pembrolizumab

Pembrolizumab through a needle or tube in a vein (intravenously, IV) every 3 weeks.

Sponsors & Collaborators

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Chelsea Salyer, MD · Massey Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2024-09-13
Completion
2024-10-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05263492 on ClinicalTrials.gov